Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.

Main purpose: Dolutegravir sodium tablets (Tevicai®, 50 mg) produced by GlaxoSmithKline Pharmaceuticals SA, licensed by ViiV Healthcare B.V., were used as the reference preparation, and dolutegravir sodium tablets provided by Shenyang First Pharmaceutical Co., Ltd., a Northeast Pharmaceutical Group (50 mg) is the test preparation. The bioequivalence of the two preparations under fasting and postprandial administration conditions was evaluated through a single-center, randomized, open-label, two-cycle, double-crossover clinical trial design. Secondary purpose: To evaluate the safety of test and reference preparations in healthy Chinese subjects.

Main purpose: To compare the empagliflozin tablets (10 mg) provided by Northeast Pharmaceutical Group Shenyang First Pharmaceutical Co., Ltd. and the licensed empagliflozin tablets (10 mg, trade name) of Boehringer Ingelheim International GmbH under fasting and postprandial administration conditions. : Jardiance®/Ou Tangjing®) in the degree and rate of absorption in healthy adults to evaluate its bioequivalence. Secondary purpose: To evaluate the comparison between empagliflozin tablets (10 mg) provided by Northeast Pharmaceutical Group Shenyang First Pharmaceutical Co., Ltd. and licensed empagliflozin tablets (10 mg, commercial product) by Boehringer Ingelheim International GmbH under fasting and postprandial administration conditions. Safety of Jardiance®/Ou Tangjing®) in healthy adults.

This trial aims to study the pharmacokinetic characteristics of healthy subjects taking a single fasting oral administration of efavirenz tablets (0.2 g) developed and produced by Northeast Pharmaceutical Group Shenyang Daiichi Pharmaceutical Co., Ltd.; Wellen Tablets (STOCRIN®, 200 mg) is a reference preparation. Compare the pharmacokinetic parameters Cmax and AUC0-72 of the two preparations, evaluate the human bioequivalence of the two preparations, and observe the safety of the two preparations in healthy subjects. sex.